Want to see USPH full AI Analyst Report?
Top Page
US Physical Therapy
(NYSE:USPH)
Select Model
Select Model
Rating:57Neutral
Price Target:
$83.00
▲(11.29% Upside)
Action:Reiterated
Date:05/20/26
The score is driven primarily by mixed fundamentals: strong multi-year revenue growth and positive free cash flow are offset by sharply compressed margins and returns. The earnings call was moderately constructive due to reaffirmed EBITDA guidance and improving demand metrics, while technicals are a notable drag given the clear downtrend. Valuation is mixed—supported by the dividend yield but clouded by a negative P/E.
Positive Factors
Sustained Revenue and Visit Growth
Multi-year top-line acceleration and rising visits indicate durable demand and stronger referral traction. Higher daily visits per clinic improve fixed-cost absorption, supporting long-term revenue stability as the network scales and same-store growth recovers, reducing reliance on one-off wins.
Negative Factors
Compressed Profitability and Weak Returns
Significant decline in net margin and ROE reflects persistent earnings pressure despite revenue growth. Lower returns reduce capital efficiency, limit reinvestment upside, and constrain long-term shareholder value creation unless operating cost trends are reversed or higher‑margin lines scale materially.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue and Visit Growth
Multi-year top-line acceleration and rising visits indicate durable demand and stronger referral traction. Higher daily visits per clinic improve fixed-cost absorption, supporting long-term revenue stability as the network scales and same-store growth recovers, reducing reliance on one-off wins.
Read all positive factors
US Physical Therapy (USPH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.22B
Dividend Yield2.3%
Average Volume (3M)217.38K
Price to Earnings (P/E)158.1
Beta (1Y)0.96
Revenue Growth13.73%
EPS Growth-77.14%
CountryUS
Employees7,294
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.50
Shares Outstanding15,218,789
10 Day Avg. Volume219,904
30 Day Avg. Volume217,381
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)2.49
Price to Sales (P/S)1.52
P/FCF Ratio19.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$92.67Price Target Upside24.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)2.8
Revenue Forecast (FY)$838.68M
US Physical Therapy Business Overview & Revenue Model
Company Description
U.S. Physical Therapy, Inc., through its various subsidiaries, manages a network of outpatient physical therapy facilities. These clinics deliver a range of services, including rehabilitation before and after surgery, treatment for musculoskeletal...
How the Company Makes Money
USPH generates revenue primarily by delivering outpatient rehabilitation services and being reimbursed for those services. The company’s core revenue stream comes from patient visits at its outpatient physical therapy clinics, where it bills third...
US Physical Therapy Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call communicated solid top-line growth, strengthening visit trends, and strategic progress (IIP margin expansion, hospital affiliations starting, expanded credit facility and targeted technology/ cash-program rollouts). Near-term pressures—weather-related lost visits, higher operating and corporate costs, elevated tax rate, and GAAP per-share impacts from revaluations—temporarily weighed on margins and net income. Management affirmed full-year adjusted EBITDA guidance, highlighted recoveries as seasonality normalizes and hospital ramps accelerate, and presented confidence in execution of strategic initiatives.Positive Updates
Revenue Growth and Visits Expansion
Total revenue of $198.0M, up 7.9% year-over-year; total patient visits 1.543M, up 6.9% YoY; daily visits per clinic increased to 31.8 from 31.2.
Negative Updates
Weather-Related Visit and Revenue Loss
Approximately 31,000 visits lost to weather in Q1, representing ~ $3.3M of revenue headwind and margin drag due to fixed payroll obligations during closures.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth and Visits Expansion
Total revenue of $198.0M, up 7.9% year-over-year; total patient visits 1.543M, up 6.9% YoY; daily visits per clinic increased to 31.8 from 31.2.
Read all positive updates
Company Guidance
Management reaffirmed full‑year 2026 adjusted EBITDA guidance of $102–$106 million, saying Q1 finished on budget with $198 million total revenue, $20.2 million adjusted EBITDA (up $0.7M year‑over‑year), 1.543 million visits (+6.9%), daily visits per clinic 31.8 (vs 31.2), net patient revenue per visit $106.49 (vs $105.66), physical therapy revenue $168M (+7.2%, same‑store +2.5%) and IIP revenue $31M (+11.8%, same‑store +8.2%) with IIP margin 20.4% (vs 18.6%) while adjusted PT margin was 16.1% (vs 16.8%); Q1 lost ~31,000 visits to weather (~$3.3M revenue impact), adjusted PT payroll/visit was $64.20 and operating costs/visit $90.31, commercial rates were up 3.4% with early benefit of a ~1.75% Medicare increase, interest expense $2.8M, tax rate 32.3%, net income attributable $5M (GAAP loss per share $0.12; operating results per share $0.46), cash $28M, borrowings $204M, a new five‑year $450M credit facility, $14M of noncontrolling interest purchases, and management expects hospital alliances (including NYU and a Gulf Coast system) and initiatives like semi‑virtual front desks, AI documentation, RTM reengagement and expanded cash‑based programs to ramp sequentially (hospital initiatives roughly $7M annualized, phased in by Q4) to drive the remainder of the year toward the guided range.US Physical Therapy Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
62
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 729.22M | 780.99M | 671.35M | 604.80M | 553.14M | 495.02M |
| Gross Profit | 149.05M | 157.34M | 123.92M | 121.51M | 112.02M | 117.18M |
| EBITDA | 103.54M | 109.66M | 86.91M | 74.37M | 76.09M | 85.73M |
| Net Income | 1.18M | 15.06M | 26.46M | 14.67M | 28.27M | 27.82M |
Balance Sheet | ||||||
| Total Assets | 1.24B | 1.20B | 1.17B | 997.24M | 858.15M | 749.43M |
| Cash, Cash Equivalents and Short-Term Investments | 28.44M | 35.57M | 41.36M | 152.82M | 31.59M | 28.57M |
| Total Debt | 362.83M | 425.74M | 295.23M | 258.59M | 295.34M | 223.08M |
| Total Liabilities | 459.19M | 433.81M | 408.42M | 345.00M | 373.59M | 296.98M |
| Stockholders Equity | 468.98M | 476.43M | 488.93M | 476.19M | 315.79M | 295.61M |
Cash Flow | ||||||
| Free Cash Flow | 66.87M | 60.99M | 65.75M | 72.68M | 50.29M | 68.20M |
| Operating Cash Flow | 83.74M | 75.06M | 74.94M | 81.98M | 58.54M | 76.41M |
| Investing Cash Flow | -70.08M | -36.71M | -149.45M | -45.02M | -81.27M | -124.14M |
| Financing Cash Flow | -24.40M | -44.14M | -36.95M | 84.27M | 25.76M | 43.38M |
US Physical Therapy Technical Analysis
Positive
74.58
Price Trends
68.49
Positive
70.33
Positive
75.45
Positive
Market Momentum
2.02
Negative
61.20
Neutral
69.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USPH, the sentiment is Positive. The current price of 74.58 is above the 20-day moving average (MA) of 74.40, above the 50-day MA of 68.49, and below the 200-day MA of 75.45, indicating a bullish trend. The MACD of 2.02 indicates Negative momentum. The RSI at 61.20 is Neutral, neither overbought nor oversold. The STOCH value of 69.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for USPH.
US Physical Therapy Risk Analysis
US Physical Therapy disclosed 27 risk factors in its most recent earnings report. US Physical Therapy reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
US Physical Therapy Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $1.58B | 13.47 | 24.12% | ― | 5.22% | 1109.87% | |
72 Outperform | $2.17B | 12.87 | 20.09% | ― | -2.25% | ― | |
71 Outperform | $1.43B | 45.30 | 9.23% | ― | 36.76% | 11.22% | |
62 Neutral | $1.35B | -39.10 | -4.98% | ― | 19.87% | 79.93% | |
57 Neutral | $1.22B | 158.12 | 0.24% | 2.44% | 13.73% | -77.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
USPH
US Physical Therapy
79.06
10.80
15.83%
AMN
AMN Healthcare Services
33.63
15.78
88.40%
HCSG
Healthcare Services
23.30
10.23
78.27%
MD
Pediatrix Medical Group
26.51
14.53
121.29%
PNTG
Pennant Group
40.32
18.25
82.69%
US Physical Therapy Corporate Events
Executive/Board ChangesShareholder Meetings
US Physical Therapy Shareholders Back Board, Pay, Auditor
Positive
May 19, 2026
On May 19, 2026, U.S. Physical Therapy, Inc. held its Annual Meeting of Shareholders, where investors voted on three governance and oversight proposals. Shareholders elected seven directors, including Christopher J. Reading and Peter F. Minan, to ...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
U.S. Physical Therapy Posts Strong Q1 2026 Revenue Growth
Positive
May 11, 2026
On May 7, 2026, U.S. Physical Therapy reported first-quarter 2026 results, highlighting a 7.9% year-over-year increase in total revenue to $198 million and a 7.2% rise in physical therapy revenue driven by higher patient volumes and a 2.5% same-st...
Dividends
US Physical Therapy Declares Quarterly Cash Dividend for Shareholders
Positive
May 6, 2026
U.S. Physical Therapy announced that its Board of Directors declared a quarterly cash dividend of $0.46 per share. The dividend is scheduled to be paid on June 12, 2026, to shareholders of record as of May 22, 2026, signaling ongoing capital retur...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.